AGTC Announces Topline Interim Six-Month Data of XLRS Gene Therapy from Ongoing Phase 1/2 Clinical Trial
Applied Genetic Technologies Corporation (AGTC) , a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase 1/2 clinical trial. The company reported that no consistently significant clinical activity from the treatment was observed after six months. AGTC will continue to analyze all of the XLRS trial data and complete all visits specified in the clinical protocol. However, if the data at additional follow-up data visits are consistent with the current six-month findings, the company has stated that they will not further develop the product. A total of 27 subjects were treated, and all completed study visits through at least six months. Thirteen adult participants received the high dose of the treatment. The study subjects also included five pediatric patients who received the medium dose, and nine adults who received medium and low doses of the gene therapy. All partici...
Comments
Post a Comment